Fundraising Fox
/Companies
Sign in

Edgewise Therapeutics

NASDAQ: EWTX

Boulder, US · Founded 2017 · 144 employees on LinkedIn · 6 known investors

Find your way into Edgewise Therapeutics

1,498 people in our graph share verified history with the Edgewise Therapeutics team — schools, employers, funds. One of them is your warm intro.

Sam Blackmanunlockedknows Badreddin Edris · together at Silverback Therapeutics (overlapped)
knows the team · via Mission Bay Capital
knows the team · via Cytokinetics
×3knows the team · via Arraybiopharma
knows the team · via OrbiMed
knows the team · via Amgen

Edgewise Therapeutics discovers and develops small molecule medicines targeting muscle proteins to treat neuromuscular and cardiac diseases, including sevasemten for muscular dystrophies and EDG-7500 for cardiomyopathy, leveraging a proprietary drug discovery platform based on muscle physiology and high-throughput functional assays.

BiotechDigital Health

Founders & leadership

Edgewise Therapeutics was founded in 2017 by Kevin Koch, Alan Russell, and Badreddin Edris.

KK
Kevin KochCo-founder · President and CEOKevin Koch is founder, president, and chief scientific officer of Edgewise Therapeutics, a public biotechnology company developing small molecule therapeutics for neuromuscular and cardiac diseases.
ARAlan Russell
Alan RussellCo-Founder & Chief Scientific OfficerCo-founder and Chief Scientific Officer of Edgewise Therapeutics, Alan Russell previously led muscle metabolism research at GlaxoSmithKline (2009–2017), where he advanced multiple clinical candidates in muscular dystrophy and muscle-wasting diseases, and earlier worked at Cytokinetics (2001–2009) as lead scientist on muscle sensitizer compounds. He holds a BPharm and PhD in Pharmacy from the University of Bath and completed postdoctoral training at Stanford University School of Medicine.
BEBadreddin Edris
Badreddin EdrisCo-Founder & Board MemberBadreddin Edris holds a Ph.D. in Genetics from Stanford University School of Medicine and has held operational and investment roles at OrbiMed Advisors, Bain & Company, and SpringWorks Therapeutics, where he served as Chief Operating Officer during the company's growth from clinical-stage to public and subsequent acquisition by Merck KGaA.
KHKenneth Harrison
Kenneth HarrisonNamed on SEC filingInvestor at Novo Holdings

Board

PTPeter Thompson
Peter ThompsonChairman, Co-FounderInvestor at OrbiMed
JR
Jonathan RootBoard directorGeneral Partner at US Venture Partners

Investors · 6

Foresite Capitallisted by Foresite CapitalWest Hollywood

How we know: Foresite Capital's portfolio page · Not right? Tell us

OrbiMedlisted by OrbiMedNew York · $1M – $75M

How we know: OrbiMed's portfolio page · the S-1 prospectus · the VCSheet dataset · Not right? Tell us

US Venture Partnerslisted by US Venture PartnersMenlo Park · $500K – $10M

How we know: US Venture Partners's portfolio page · Not right? Tell us

Deerfield Management CompanyreportedNew York

How we know: the S-1 prospectus · Not right? Tell us

Novo HoldingsreportedCopenhagen · $1.1M – $54M

How we know: the S-1 prospectus · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$120.1M disclosed across 2 rounds · 2019–2020

▶$95MraisedDec 2020 · 21 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kevin KochExecutive Officer, Director
  • Peter ThompsonDirector
  • Kenneth HarrisonDirector
  • Jonathan RootDirector
  • Alan RussellDirector
Offering amount
$95M
Amount sold
$95M
First sale
Dec 2020
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$25.1MraisedSep 2019 · 6 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kevin KochExecutive Officer, Director
  • Peter ThompsonDirector
  • Kenneth HarrisonDirector
  • Jonathan RootDirector
  • Alan RussellDirector
Offering amount
$50.1M
Amount sold
$25.1M
First sale
Aug 2019
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$761.3Mvaluation at IPOMar 2021 · $16.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Founder mafia

4 people who came through Edgewise Therapeutics went on to found or lead other companies.

Peter ThompsonDirectorFounded Cleave Biosciences +3Peter Thompson, M.D.Chairman, Co-FounderFounded Cleave Biosciences +3Kevin KochExecutive Officer, DirectorFounded ArraybiopharmaBadreddin EdrisDirector and Co-FounderFounded Silverback Therapeutics

Frequently asked questions

What does Edgewise Therapeutics do?
Edgewise Therapeutics discovers and develops small molecule medicines targeting muscle proteins to treat neuromuscular and cardiac diseases, including sevasemten for muscular dystrophies and EDG-7500 for cardiomyopathy, leveraging a proprietary drug discovery platform based on muscle physiology and high-throughput functional assays.
Who founded Edgewise Therapeutics?
Edgewise Therapeutics was founded by Kevin Koch, Alan Russell, Badreddin Edris in 2017.
Who are Edgewise Therapeutics's investors?
Edgewise Therapeutics's investors include Boulder Ventures, Foresite Capital, OrbiMed, US Venture Partners, Deerfield Management Company, Novo Holdings.
How much funding has Edgewise Therapeutics raised?
Edgewise Therapeutics has disclosed $120.1M raised across 2 rounds.
Where is Edgewise Therapeutics headquartered?
Edgewise Therapeutics is headquartered in Boulder, US.